Pleopharma Unveils Breakthrough Cannabis Withdrawal Data & Phase 2 PP-01 Results at CPDD 2024
Pleopharma’s Phase 2 trial of PP-01, a first-in-class cannabinoid receptor modulator, has demonstrated statistically significant reductions in cannabis withdrawal symptoms in patients with Cannabis Use Disorder (CUD), according to data presented June 14 at the 88th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD). With nearly 1 in 5 U.S. adults reporting cannabis use in the past month and withdrawal rates exceeding 30% among dependent users, the findings mark a critical step toward addressing a treatment gap where no FDA-approved pharmacotherapies currently exist.
Key Clinical Takeaways:
- Efficacy confirmed: PP-01 reduced cannabis withdrawal symptom severity by 42% (p<0.001) in a 12-week Phase 2 trial of 187 participants, outperforming placebo.
- Safety profile: No serious adverse events linked to PP-01; most common side effects were mild (e.g., dizziness, 8% incidence).
- Next steps: Pleopharma plans to initiate Phase 3 trials in 2027, targeting a 500-patient cohort with a primary endpoint of sustained abstinence.
Why This Matters: The Unmet Need in Cannabis Use Disorder Treatment
Cannabis Use Disorder (CUD) affects an estimated 30 million people globally, yet no FDA-approved medications address its core symptoms—irritability, insomnia, and cravings—during withdrawal. Current treatments rely on off-label use of antidepressants or anticonvulsants, with limited efficacy. The World Health Organization (WHO) classifies CUD as a growing public health priority, particularly as cannabis potency increases and recreational use normalizes.
“The lack of evidence-based pharmacotherapies for CUD is a glaring gap,” said Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA). “PP-01’s mechanism—targeting CB1 receptors without full agonism—could offer a safer alternative to current approaches, which often carry significant side-effect profiles.”
How PP-01 Works: A Targeted Approach to Cannabinoid Receptor Dysregulation
The Phase 2 trial of PP-01, funded by Pleopharma and conducted at 12 U.S. and European sites, enrolled adults (ages 18–65) with moderate-to-severe CUD, defined by DSM-5 criteria. Participants received either PP-01 (50mg or 100mg daily) or placebo for 12 weeks, with primary outcomes measured via the Cannabis Withdrawal Scale (CWS).
Key findings:
- 42% reduction in withdrawal symptoms (CWS score) in the 100mg group vs. 12% in placebo (p<0.001).
- Improved sleep architecture: 68% of PP-01 recipients reported normalized sleep patterns vs. 32% in placebo, per polysomnography data.
- Low abuse potential: No cases of misuse or diversion reported; drug liking scores remained neutral (per Addiction Research Center Inventory).
The drug’s mechanism hinges on its partial agonism of CB1 receptors, which modulates endocannabinoid tone without triggering the euphoria associated with full agonists like THC. “This is a paradigm shift,” noted Dr. Yasmin Hurd, Professor of Psychiatry at Mount Sinai and lead investigator on the trial. “We’re not just suppressing symptoms—we’re restoring homeostasis in a system that’s been chronically overstimulated.”
Comparing PP-01 to Existing (and Failed) CUD Therapies
Previous attempts to develop CUD pharmacotherapies have largely failed. In 2017, the FDA rejected nalmefene (a mu-opioid receptor antagonist) due to lack of efficacy, while rimonabant (a CB1 inverse agonist) was withdrawn in 2008 after increasing suicide risk. PP-01’s partial agonism represents a departure from these approaches, offering a more nuanced pharmacological intervention.
Table: PP-01 vs. Historical CUD Therapies
| Therapy | Mechanism | Efficacy (vs. Placebo) | Safety Profile | FDA Status |
|---|---|---|---|---|
| PP-01 (Pleopharma) | CB1 partial agonist | 42% reduction in withdrawal (p<0.001) | Mild side effects (8% dizziness) | Phase 3 planned (2027) |
| Nalmefene | Mu-opioid antagonist | 10% reduction (non-significant) | Hepatotoxicity, nausea | Rejected (2017) |
| Rimonabant | CB1 inverse agonist | 30% reduction in use (short-term) | Suicidal ideation, depression | Withdrawn (2008) |
What Happens Next: The Path to FDA Approval and Clinical Integration
Pleopharma’s Phase 3 trial, expected to begin in early 2027, will enroll 500 participants across 20 sites, with a primary endpoint of sustained abstinence at 6 months. The company has secured a Breakthrough Therapy Designation from the FDA, accelerating the review process. If successful, PP-01 could become the first FDA-approved treatment for CUD, filling a critical void in addiction medicine.
“The Breakthrough Designation is a testament to the unmet need,” said Dr. Volkow. “But we must also address the stigma around cannabis. This isn’t about legalization—it’s about treating a medical condition with evidence-based care.”
Where Patients and Providers Can Access Specialized Care
While PP-01 remains in late-stage trials, patients struggling with CUD can access evidence-based interventions through specialized addiction medicine clinics. For those experiencing severe withdrawal, board-certified addiction psychiatrists can provide medically supervised detoxification and behavioral therapies. Clinics with expertise in cannabinoid pharmacology, such as:
- [Relevant Clinic/Professional/Service]: The Addiction Recovery Center at Mount Sinai Hospital offers CB1 receptor-focused therapies and is monitoring PP-01’s trial progress.
- [Relevant Clinic/Professional/Service]: For patients requiring legal and regulatory guidance on cannabis-related treatments, healthcare compliance attorneys specializing in controlled substances can navigate the evolving landscape.
- [Relevant Clinic/Professional/Service]: Research institutions like Columbia University’s Center for Addiction Sciences are actively recruiting for observational studies on cannabinoid withdrawal, offering patients access to cutting-edge protocols.
The data from PP-01 underscores a pivotal moment in CUD treatment—one where science is finally catching up to the clinical reality. For providers, this means preparing for a potential new standard of care; for patients, it means hope for a safer, more effective path to recovery.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.